Company Profiles

driven by the PitchBook Platform

Ensemble Therapeutics

Description

Developer of macrocycle drugs based on a DNA-programmed chemistry drug discovery platform for the pharmaceutical industry. The company offers Ensemblins, a synthetic macrocycle drug to treat diseases by addressing drug targets, such as protein-protein or protein-peptide interactions, phosphatases, and proteases. It is developing a pipeline of macrocycle product candidates to use in inflammation, oncology, pain and diabetes markets.

2002

Founded

PRIVATE

Status

11-50

Employees

Grant

Latest Deal Type

$740k

Latest Deal Amount

$38.2M

Total Amount Raised

Description

Developer of macrocycle drugs based on a DNA-programmed chemistry drug discovery platform for the pharmaceutical industry. The company offers Ensemblins, a synthetic macrocycle drug to treat diseases by addressing drug targets, such as protein-protein or protein-peptide interactions, phosphatases, and proteases. It is developing a pipeline of macrocycle product candidates to use in inflammation, oncology, pain and diabetes markets.

Website:

www.ensembletx.com

Formerly Known As

Ensemble Discovery Corporation

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Pharmaceuticals

Primary Office

99 Erie Street Cambridge, MA 02139United States +1 (617) 492-6977
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Ensemble Therapeutics's full profile, request a free trial.

Ensemble Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Ensemble Therapeutics Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Ensemble Therapeutics Investors (12)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Agile EquitiesVenture CapitalMinority000 0000000 0000
Applied Genomic Technology Capital FundVenture CapitalMinority000 0000000 0000
ARCH Venture PartnersVenture CapitalMinority000 0000000 0000
Boston University EndowmentLimited PartnerMinority000 0000000 0000
Flagship VenturesVenture CapitalMinority000 0000000 0000
Agile Equities Venture Capital
Applied Genomic Technology Capital Fund Venture Capital
ARCH Venture Partners Venture Capital
Boston University Endowment Limited Partner
Flagship Ventures Venture Capital

Ensemble Therapeutics Executive Team (5)

NameTitleBoard
Seat
Contact
Info
John RippleChief Executive Officer & Board Member
Nick TerrettChief Scientific Officer
Ted HibbenSenior Vice President, Corporate Development
Stephen Hale Ph.DSenior Vice President, Biological Sciences
Andrea Szekely-HillVice President, Finance & Administration
John Ripple Chief Executive Officer & Board Member
Nick Terrett Chief Scientific Officer
Ted Hibben Senior Vice President, Corporate Development
Stephen Hale Ph.D Senior Vice President, Biological Sciences
Andrea Szekely-Hill Vice President, Finance & Administration

Ensemble Therapeutics Board Members (9)

NameRepresentingRoleSinceContact
Info
David Berry Ph.DFlagship VenturesBoard Member000 0000
Douglas Cole MDFlagship VenturesBoard Member000 0000
Ian Chia Ph.DHarris & Harris GroupBoard Observer000 0000
John RippleSelfChief Executive Officer & Board Member000 0000
Karl HandelsmanPresidio PartnersBoard Observer000 0000
David Berry Ph.D Board Member Flagship Ventures
Douglas Cole MD Board Member Flagship Ventures
Ian Chia Ph.D Board Observer Harris & Harris Group
John Ripple Chief Executive Officer & Board Member Self
Karl Handelsman Board Observer Presidio Partners
Request full access to PitchBook